These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3372645)

  • 21. Separation and quantitation of debrisoquine and 4-hydroxydebrisoquine in human urine by capillary electrophoresis and high-performance liquid chromatography.
    Cifuentes A; Valencia J; Sanz E; Sánchez MJ; Rodríguez-Delgado MA
    J Chromatogr A; 1997 Aug; 778(1-2):389-96. PubMed ID: 9299748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of debrisoquine and its 4-hydroxy metabolite in urine by high-performance liquid chromatography.
    Harrison PM; Tonkin AM; Dixon ST; McLean AJ
    J Chromatogr; 1986 Jan; 374(1):204-8. PubMed ID: 3949931
    [No Abstract]   [Full Text] [Related]  

  • 23. High-performance liquid chromatographic determination of carbamazepine and carbamazepine 10,11-epoxide in plasma and saliva following solid-phase sample extraction.
    Hartley R; Lucock M; Cookman JR; Becker M; Smith IJ; Smithells RW; Forsythe WI
    J Chromatogr; 1986 Aug; 380(2):347-56. PubMed ID: 3760062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-performance liquid chromatographic method for the analysis of debrisoquine and its S-(+)- and R-(-)-hydroxy metabolites in urine.
    Meese CO; Thalheimer P; Eichelbaum M
    J Chromatogr; 1987 Dec; 423():344-50. PubMed ID: 3443671
    [No Abstract]   [Full Text] [Related]  

  • 25. Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.
    Allen JG; East PB; Francis RJ; Haigh JL
    Drug Metab Dispos; 1975; 3(5):332-7. PubMed ID: 241613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of stereoselectivity and genetic polymorphism of the debrisoquine hydroxylation in man via analysis of urinary debrisoquine and 4-hydroxydebrisoquine by capillary electrophoresis.
    Lanz M; Theurillat R; Thormann W
    Electrophoresis; 1997 Sep; 18(10):1875-81. PubMed ID: 9372283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphic hydroxylation of Debrisoquine in man.
    Mahgoub A; Idle JR; Dring LG; Lancaster R; Smith RL
    Lancet; 1977 Sep; 2(8038):584-6. PubMed ID: 71400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results.
    Vincent-Viry M; Deshayes S; Mothe O; Siest G; Galteau MM
    J Pharm Pharmacol; 1988 Oct; 40(10):695-700. PubMed ID: 2907535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gas chromatography/mass spectrometry assays for the determination of debrisoquine and sparteine metabolites in microsomal fractions of rat liver.
    Ho JW; Moody DE
    Anal Biochem; 1992 Jun; 203(2):348-51. PubMed ID: 1416032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The metabolism of [14C]-debrisoquine in man.
    Idle JR; Mahgoub A; Angelo MM; Dring LG; Lancaster R; Smith RL
    Br J Clin Pharmacol; 1979 Mar; 7(3):257-66. PubMed ID: 371651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
    Alván G; Grind M; Graffner C; Sjöqvist F
    Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-performance of liquid chromatographic determination of [3,4-di-(4-methoxyphenyl)-5-isoxazolyl]acetic acid and its metabolites in human plasma and urine.
    Marunaka T; Maniwa M
    J Chromatogr; 1987 Nov; 422():227-33. PubMed ID: 3501788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-performance liquid chromatographic determination of pyrazinamide in cerebrospinal fluid and plasma in the rabbit.
    Chan K; Wong CL; Lok S
    J Chromatogr; 1986 Aug; 380(2):367-73. PubMed ID: 3760064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans.
    Eiermann B; Edlund PO; Tjernberg A; Dalén P; Dahl ML; Bertilsson L
    Drug Metab Dispos; 1998 Nov; 26(11):1096-101. PubMed ID: 9806952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
    Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J
    Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Micro-method for the determination of piperacillin in plasma by high-performance liquid chromatography.
    Gautier V; Demotes-Mainard F; Foureau M; Vinçon G
    J Pharm Biomed Anal; 1991; 9(2):183-6. PubMed ID: 1873310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
    Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.